Aguinaga Aitziber, Díaz-González Jorge, Pérez-García Alejandra, Barrado Laura, Martínez-Baz Iván, Casado Itziar, Juanbeltz Regina, Ezpeleta Carmen, Castilla Jesús
Servicio de Microbiología Clínica, Complejo Hospitalario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Navarra, España.
Instituto de Salud Pública de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Navarra, España.
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Jun-Jul;36(6):325-331. doi: 10.1016/j.eimc.2016.12.008. Epub 2017 Jan 19.
To estimate the prevalence of hepatitis C virus (HCV) infection in Navarra, Spain, as well as to distinguish between diagnosed and undiagnosed infections.
A study was conducted on patients scheduled for surgery unrelated to HCV infection. They were all tested for HCV antibodies, under a routine scheme, from January 2014 to September 2016. Patients with a positive result by enzyme immunoassay were confirmed using immunoblot and/or HCV-RNA. Previous laboratory results were also taken into account. The prevalence was adjusted to the sex and age structure of the Navarra population.
The study included a total of 7,378 patients with a median age 46 years, of whom 50% women. HCV antibodies were detected in 69 patients, which is a prevalence in the population of 0.83% (95% confidence interval: 0.64-1.05), and was higher in men (1.11%) than in women (0.56%; P=.0102). Among the HCV positive patients, 67 (97%) had had another previous positive result. Population prevalence of previous positive HCV was 0.80%, and was 0.03% for a new diagnosis. Of the HCV positive patients, 78% had detectable HCV-RNA. It was estimated that 0.65% of the population had had detectable HCV-RNA, and 0.51% continued to have it when recruited into the study.
Previous estimates of prevalence of HCV infection should be revised downwards. Only a small proportion of HCV positive patients remain undiagnosed, and only a small part have active infection.
评估西班牙纳瓦拉地区丙型肝炎病毒(HCV)感染的患病率,并区分已诊断和未诊断的感染情况。
对计划进行与HCV感染无关手术的患者开展一项研究。在2014年1月至2016年9月期间,按照常规方案对他们进行HCV抗体检测。酶免疫测定结果呈阳性的患者,采用免疫印迹法和/或HCV-RNA进行确诊。同时也考虑既往实验室检测结果。患病率根据纳瓦拉地区人群的性别和年龄结构进行调整。
该研究共纳入7378例患者,中位年龄为46岁,其中50%为女性。69例患者检测出HCV抗体,人群患病率为0.83%(95%置信区间:0.64 - 1.05),男性患病率(1.11%)高于女性(0.56%;P = 0.0102)。在HCV阳性患者中,67例(97%)既往曾有过阳性结果。既往HCV阳性的人群患病率为0.80%,新诊断的患病率为0.03%。在HCV阳性患者中,78%可检测到HCV-RNA。据估计,0.65%的人群曾检测到HCV-RNA,而在纳入研究时,0.51%的人群仍可检测到。
既往对HCV感染患病率的估计应向下修正。只有一小部分HCV阳性患者仍未被诊断,且仅有一小部分存在活动性感染。